Bufotalin dry powder inhalers and preparation method as well as application thereof

A technology of bufatalin and dry powder inhaler, which is applied in pharmaceutical formulations, powder delivery, respiratory diseases and other directions to achieve the effects of high patient compliance, less adverse reactions and convenient application.

Active Publication Date: 2011-11-23
陈彦
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no research report on Bufatalin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Preparation of inhalation: bufatolin was pulverized to D 50 = less than 6 microns, mixed with lactose having a particle size of 75-100 microns in a mass ratio of 1:9, and packing the drug powder into capsules or blisters or dry powder inhalers to obtain inhalants.

Embodiment 2

[0024] Preparation of inhalation: bufatolin was pulverized to D 50 = 4 microns, mixed with lactose with a particle size of 75-90 microns and leucine with a particle size of 45-65 microns in a ratio of 10:90:1, packed into capsules or blisters or dry powder inhalers to obtain inhalant.

Embodiment 3

[0026] Preparation of inhalation: bufatolin was pulverized to D 50 = 4 microns, mixed with leucine with a particle size of 75-125 microns at a ratio of 1:9, packed into capsules or blisters or dry powder inhalers to obtain inhalers.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to dry powder inhalers, in particular to dry powder inhalers prepared from bufotalin, a preparation method of the dry powder inhalers and application of the dry powder inhalers to preparation of medicaments for treating lung tumor medicaments. The bufotalin dry powder inhalers are characterized by consisting of bufotalin and a medically acceptable auxiliary material according to the mass ratio of (1:0.05)-(1:115). The bufotalin is prepared into the dry powder inhalers which can directly act on a focus of lung, so that toxic or side reaction is reduced, bioavailability ofthe medicament is improved, the defects of slow response, hepatic first-pass effect, systemic toxic or side effect, low bioavailability and the like of an oral preparation can be overcome, meanwhile,the problems of inconvenience for use, poor compliance of a patient and the like of injection can also be solved. Thus, the method of preparing the bufotalin into the dry powder inhalers has broad prospect on development of new medicaments.

Description

Technical field: [0001] The invention relates to a dry powder inhaler, specifically a dry powder inhaler made of bufafetalin, a preparation method of the dry powder inhaler and an application in the preparation of a drug for treating lung tumors. Background technique: [0002] Toad poison is the main active ingredient in toad venom. It is a cardiac glycoside substance, white crystal, fat-soluble substance, and its molecular formula is: C 26 h 36 o 6 , has pharmacological effects such as anti-tumor, analgesic and cardiotonic, anti-inflammatory and immune-enhancing. At present, oral liquids and tablets containing bufaduling have been used clinically, and have good curative effects on liver cancer, lung cancer, gastric cancer, etc. Bufatalin is highly toxic and can cause systemic side effects after oral administration. Moreover, due to the first-pass effect of the liver, it is not conducive to drug accumulation in the tumor site, so the onset of action is slow, and the bioav...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/72A61K9/14A61K31/585A61K47/26A61P35/00A61P11/00
Inventor 陈彦张振海贾晓斌杜萌刘璇
Owner 陈彦
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap